Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors

F. Janku; R. Abdul-Karim; A. Azad; J. Bendell; H. Gan; S. Sen; T. Tan; J. Wang; N. Marina; L. Baker; L. Ma; J. Mooney; D. Luo; J. Leveque; M. Milla; T. Meniawy

doi:10.1016/S0959-8049(20)31094-7

Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors

F. Janku, R. Abdul-Karim, A. Azad, J. Bendell, H. Gan, S. Sen, T. Tan, J. Wang, N. Marina, L. Baker, L. Ma, J. Mooney, D. Luo, J. Leveque, M. Milla, T. Meniawy

Medicine Monash Health

Research output: Contribution to journal › Meeting Abstract › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	S11
Number of pages	1
Journal	European Journal of Cancer
Volume	138
Issue number	S2
DOIs	https://doi.org/10.1016/S0959-8049(20)31094-7
Publication status	Published - Oct 2020
Event	EORTC/AACR/NCI International Conference on Molecular Targets and Cancer Therapeutics 2020 - Virtual Conference Duration: 24 Oct 2020 → 25 Oct 2020 Conference number: 32nd https://www.ejcancer.com/issue/S0959-8049(20)X0017-7

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0959-8049(20)31094-7

Cite this

Janku, F., Abdul-Karim, R., Azad, A., Bendell, J., Gan, H., Sen, S., Tan, T., Wang, J., Marina, N., Baker, L., Ma, L., Mooney, J., Luo, D., Leveque, J., Milla, M., & Meniawy, T. (2020). Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors. European Journal of Cancer, 138(S2), S11. https://doi.org/10.1016/S0959-8049(20)31094-7

@article{287bc61bd0764226b7d28156c1a14395,

title = "Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors",

author = "F. Janku and R. Abdul-Karim and A. Azad and J. Bendell and H. Gan and S. Sen and T. Tan and J. Wang and N. Marina and L. Baker and L. Ma and J. Mooney and D. Luo and J. Leveque and M. Milla and T. Meniawy",

note = "Saturday, 24 October 2020 20:45–21:35 POSTER DISCUSSION SESSION New Therapeutics in Phase I and II studies; EORTC/AACR/NCI International Conference on Molecular Targets and Cancer Therapeutics 2020, EORTC/AACR/NCI 2020 ; Conference date: 24-10-2020 Through 25-10-2020",

year = "2020",

month = oct,

doi = "10.1016/S0959-8049(20)31094-7",

language = "English",

volume = "138",

pages = "S11",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier",

number = "S2",

url = "https://www.ejcancer.com/issue/S0959-8049(20)X0017-7",

}

Janku, F, Abdul-Karim, R, Azad, A, Bendell, J, Gan, H, Sen, S, Tan, T, Wang, J, Marina, N, Baker, L, Ma, L, Mooney, J, Luo, D, Leveque, J, Milla, M & Meniawy, T 2020, 'Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors', European Journal of Cancer, vol. 138, no. S2, pp. S11. https://doi.org/10.1016/S0959-8049(20)31094-7

Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors. / Janku, F.; Abdul-Karim, R.; Azad, A. et al.
In: European Journal of Cancer, Vol. 138, No. S2, 10.2020, p. S11.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors

AU - Janku, F.

AU - Abdul-Karim, R.

AU - Azad, A.

AU - Bendell, J.

AU - Gan, H.

AU - Sen, S.

AU - Tan, T.

AU - Wang, J.

AU - Marina, N.

AU - Baker, L.

AU - Ma, L.

AU - Mooney, J.

AU - Luo, D.

AU - Leveque, J.

AU - Milla, M.

AU - Meniawy, T.

N1 - Conference code: 32nd

PY - 2020/10

Y1 - 2020/10

UR - http://www.scopus.com/inward/record.url?scp=85093929499&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(20)31094-7

DO - 10.1016/S0959-8049(20)31094-7

M3 - Meeting Abstract

AN - SCOPUS:85093929499

SN - 0959-8049

VL - 138

SP - S11

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - S2

T2 - EORTC/AACR/NCI International Conference on Molecular Targets and Cancer Therapeutics 2020

Y2 - 24 October 2020 through 25 October 2020

ER -

Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors

UN SDGs

Access to Document

Other files and links

Cite this